Physician profile
Barry Donner
NPI 1679534796
$5,254.60
in general payments reported to CMS, 2019-2025
32 companies · $1,290 in 2025
The $1,290 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $971 · 2020: $226 · 2021: $151 · 2022: $463 · 2023: $884 · 2024: $1,269 · 2025: $1,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,425 · Education: $19.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,424.55 |
| Education | $19.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,368.48 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Genzyme Corporation | $435.18 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $430.98 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $320.54 | 2019-2025 | |
| Janssen Biotech, INC. | $193.49 | 2019-2025 | Stelara, Remicade, Simponi |
| Travere Therapeutics, INC. | $149.24 | 2025 | |
| Intercept Pharmaceuticals, INC. | $148.45 | 2019-2023 | Ocaliva |
| Mirum Pharmaceuticals, INC. | $130.68 | 2025 | Livmarli |
| Celltrion USA INC. | $108.97 | 2024-2025 | Zymfentra, Vegzelma |
| Regeneron Healthcare Solutions, INC. | $98.38 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $90.34 | 2024-2025 | Omvoh, Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $74.51 | 2019-2024 | Entyvio |
| Qol Medical, LLC | $73.00 | 2019 | |
| Madrigal Pharmaceuticals | $71.41 | 2025 | Rezdiffra |
| Ucb, INC. | $64.50 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $60.31 | 2019-2020 | |
| Vivus LLC | $55.79 | 2022-2024 | Qsymia |
| Astrazeneca Pharmaceuticals Lp | $52.93 | 2019-2024 | Wainua |
| Braintree Laboratories, INC. | $48.67 | 2023-2025 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $37.43 | 2022-2023 | Rebyota |
| Novo Nordisk INC | $31.35 | 2025 | Sogroya |
| Tempus Ai, INC | $26.72 | 2024 | |
| Boston Scientific Corporation | $25.72 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $24.37 | 2023 | Crysvita |
| Glaxosmithkline, LLC. | $24.28 | 2019 | |
| Scpharmaceuticals INC. | $21.10 | 2025 | |
| Redhill Biopharma INC. | $20.65 | 2023 | Talicia |
| Aimmune Therapeutics, INC. | $19.08 | 2024 | |
| Merck Sharp & Dohme LLC | $16.39 | 2022 | |
| Echosens North America, INC. | $16.10 | 2019 | |
| Shionogi INC | $15.56 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$161,100.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Donner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.